Cancer drug fails to impress in early head and neck cancer trial
NCT ID NCT04169074
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 33 times
Summary
This study tested the drug abemaciclib given for 10-21 days before surgery in people with HPV-negative head and neck cancer. The goal was to see if it could shrink tumors and was safe. Only 7 people took part before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
George Washington Cancer Center
Washington D.C., District of Columbia, 20037, United States
-
University of Arizona
Tucson, Arizona, 85719, United States
Conditions
Explore the condition pages connected to this study.